Fredag 27 December | 01:00:48 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-08-21 08:30 Kvartalsrapport 2025-Q2
2025-04-30 08:30 Kvartalsrapport 2025-Q1
2025-02-13 08:30 Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-04-30 - Kvartalsrapport 2024-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
NanoEcho är verksamt inom sjukvården, med huvudsaklig fokus inom rektalcancerdiagnostik. Bolaget är verksamt i kliniskt skede, där man utvecklar en ny diagnostisk metod för att fastställa om tidig rektalcancer har spridit sig till närliggande lymfkörtlar. Metoden ämnar ge en korrekt diagnos och individanpassad behandling. NanoEcho grundades år 2013 och har sitt huvudkontor i Lund.
2024-06-27 08:30:00

After an extensive review process, NanoEcho's quality management system has today become ISO 13485 certified. This means that NanoEcho operates in accordance with the legal requirements for medtech companies, necessary for launching medical devices in the EU.

This certification is in practice a legal requirement for the company to be allowed to launch medical devices on the European market, according to the EU's medical technology regulations (MDR 2017/745).

"Today, completely according to plan, we have passed this significant milestone. We have carefully built a comprehensive quality management system, which has now undergone a thorough third-party review process. This proves that we work efficiently and structured as a medtech company, which forms a valuable basis for both our clinical phase and our upcoming market introduction", says Linda Persson, CEO at NanoEcho.

The certificate was issued by BSI Group The Netherlands B.V. after they carried out an extensive review of the company's work processes. BSI Group is authorised by the European Medicines Agency to ensure that the quality management system meets relevant laws and standards.
 
The certification facilitates the possibility of launching medical technology devices also in countries outside Europe.